TY - JOUR
T1 - Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
AU - Telli, Melinda L.
AU - Tolaney, Sara M.
AU - Shapiro, Geoffrey I.
AU - Middleton, Mark
AU - Lord, Simon R.
AU - Arkenau, Hendrik Tobias
AU - Tutt, Andrew
AU - Abramson, Vandana
AU - Dean, Emma
AU - Haddad, Tufia C.
AU - Wesolowski, Robert
AU - Ferrer-Playan, Jordi
AU - Goddemeier, Thomas
AU - Grombacher, Thomas
AU - Dong, Jennifer
AU - Fleuranceau-Morel, Patricia
AU - Diaz-Padilla, Ivan
AU - Plummer, Ruth
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.
AB - Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.
UR - http://www.scopus.com/inward/record.url?scp=85128048878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128048878&partnerID=8YFLogxK
U2 - 10.1038/s41523-022-00406-0
DO - 10.1038/s41523-022-00406-0
M3 - Article
AN - SCOPUS:85128048878
SN - 2374-4677
VL - 8
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 45
ER -